Antihypertensive Medications and the Risk of Sepsis: Hypertension Clinical Trial… | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Key Updates for Angina, NSTEMI

The overtreatment of ‘mild’ hypertension is causing more harm than good, say … – MinnPost »

Antihypertensive Medications and the Risk of Sepsis: Hypertension Clinical Trial…

September 26, 2014 by 2012pharmaceutical

The primary objective of this study was to assess whether there is an increased risk of sepsis with the use of telmisartan compared with other ARBs and with…

Source: clinicaltrialsfeeds.org

See on Scoop.it – Cardiotoxicity

Posted in Uncategorized | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,058 other subscribers

Email Address
Recent Posts
- Goal Attainment Scaling Record: 2021 – A Year in Review January 4, 2022
- Debbie Nickerson Dies at 67 – Greatest Loss to Genomic Sciences, yet January 3, 2022
- New studies link cell cycle proteins to immunosurveillance of premalignant cells December 16, 2021
- Global Alliance for Genomics and Health Issues Guidelines for Data Siloing and Sharing December 14, 2021
- UK Biobank Makes Available 200,000 whole genomes Open Access December 7, 2021
- FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism November 22, 2021
- Defective viral RNA sensing gene OAS1 linked to severe COVID-19 November 22, 2021
- Moderna Vaccine Patent Application needs to include Names of Three NIH Scientists that Shared the Genome Sequence of SAR-Cov-2 with Moderna Early on November 11, 2021
- Epidemiologic measurement on COVID-19 pandemic may have statistical biases which might affect next variant responses November 7, 2021
- The Vibrant Philly Biotech Scene: Proteovant Therapeutics Using Artificial Intelligence and Machine Learning to Develop PROTACs October 26, 2021
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: